Log in to search using one of your social media accounts:

 

Dumfries Infirmary renal cancer diagnosis delay apology ordered
A complaint is upheld about the time it took to provide a man with treatment at Dumfries Infirmary. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 25, 2018 Category: Consumer Health News Source Type: news

Significant advances detected in knowledge about renal cancer
(University of the Basque Country) The prestigious journal Cell is today publishing three papers on renal cancer signed by an interdisciplinary group known as the TRACERx Renal Consortium, a member of which is Dr Jose Ignacio L ó pez, a pathologist at University Hospital Cruces and tenured lecturer in the Faculty of Medicine and Nursing of the UPV/EHU-University of the Basque Country. These studies offer fresh data on different aspects of the biology of renal cancer which could help to improve predictions and possible therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 24, 2018 Category: International Medicine & Public Health Source Type: news

Nivolumab/Ipilimumab Combo Approved for Advanced RCC
In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Dylan Fisher Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Argos discontinues troubled trial, delists from Nasdaq
Argos made a series of announcements Thursday that reflect troubles stemming from a challenging 2017. The company has said it will discontinue its lead clinical trial, move from the Nasdaq to an OTC market and has hired a financial advisor to help consider its alternatives. Argos (Nasdaq: ARGS) disclosed Thursday that – based on new interim results – it decided to discontinue its phase 3 ADAPT trial of Rocapuldencel-T for the treatment of metastatic kidney cancer and has notified the U.S. Food… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 19, 2018 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

FDA approves Opdivo, Yervoy combination for kidney cancer
The Food and Drug Administration has approved a combination of two immunotherapy drugs, ipilimumab and nivolumab, to treat metastatic kidney cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 17, 2018 Category: Consumer Health News Source Type: news

JAMA: Payments influence oncologist prescribing
Lead study author Aaron Mitchell said they also found prescriptions increased as the amount of money physicians received went up. Payments for research, by contrast, were not associated with statistically significant differences in prescribing.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

First step to kidney cancer may occur in childhood
A single damaged cell may be all it takes to trigger aggressive and terminal kidney cancer almost a lifetime after the first step towards the disease is taken.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

FDA approves combination for advanced renal cell carcinoma
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

FDA approves new standard of care for kidney cancer
(UT Southwestern Medical Center) The US Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2018 Category: International Medicine & Public Health Source Type: news

Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
Antibiotics administered within 30 days of starting immunotherapy reduced both PFS and OS for patients with advanced RCC and NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

FDA Approves IO Combo for Advanced Renal Cell Cancer FDA Approves IO Combo for Advanced Renal Cell Cancer
The approval of the nivolumab and ipilimumab combination provides a new first-line treatment option for a segment of patients with advanced renal cell carcinoma.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Drug Combo Wins OK as First Line in Kidney Cancer
(MedPage Today) -- As shown in Checkmate 214 study, ipilimumab + nivolumab improve survival (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 16, 2018 Category: Urology & Nephrology Source Type: news

'Seeds' of kidney cancer are planted in childhood
Researchers from the Francis Crick Institute, London, found certain kidney tumours have extensive mutations and are likely to spread, while benign forms of the disease grow slowly. (Source: the Mail online | Health)
Source: the Mail online | Health - April 13, 2018 Category: Consumer Health News Source Type: news

Cancer Can Start To Develop Fifty Years Before Diagnosis
Scientists studying kidney cancer have found that the first genetic damage eventually leading to cancer can occur as early as childhood, in some cases fifty years before diagnosis. They hope this information can be used to help detect these cancers earlier and guide personalized treatment. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 12, 2018 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Source Type: news

Kidney cancer may begin developing in childhood years before disease diagnosis
SEEDS of kidney cancer may be planted in childhood or adolescence, decades before the disease is diagnosed, scientists have learned. The common fault, caused by the botched repair of broken chromosomes, remains hidden and harmless in the majority of the population. (Source: Daily Express - Health)
Source: Daily Express - Health - April 12, 2018 Category: Consumer Health News Source Type: news

First seeds of kidney cancer sown in adolescence
(Wellcome Trust Sanger Institute) The earliest critical genetic changes that can lead to kidney cancer have been mapped by scientists. The first key genetic change occurs in childhood or adolescence, and the resulting cells follow a consistent path to progress into kidney cancer four or five decades later, scientists from the Wellcome Sanger Institute and their collaborators have found. Insights from the study present an opportunity to develop approaches for early detection and early intervention in kidney cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 12, 2018 Category: Biology Source Type: news

'Killer' kidney cancers identified by studying their evolution
(The Francis Crick Institute) Scientists have discovered that kidney cancer follows distinct evolutionary paths, enabling them to detect whether a tumor will be aggressive and revealing that the first seeds of kidney cancer are sown as early as childhood. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2018 Category: Cancer & Oncology Source Type: news

Kidney cancer warning - why you should never ignore a pain in your side
CANCER symptoms vary depending on which part of the body is affected by a tumour. You could be at risk of kidney cancer if you ’re showing signs of a pain in your side. (Source: Daily Express - Health)
Source: Daily Express - Health - April 11, 2018 Category: Consumer Health News Source Type: news

Belly Fat Tied to Lower Kidney Cancer Survival Odds in Women
Title: Belly Fat Tied to Lower Kidney Cancer Survival Odds in WomenCategory: Health NewsCreated: 4/9/2018 12:00:00 AMLast Editorial Review: 4/10/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 10, 2018 Category: Cancer & Oncology Source Type: news

Belly Fat Tied to Lower Kidney Cancer Survival Odds in Women
(Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - April 10, 2018 Category: Cancer & Oncology Source Type: news

Nivolumab/Ipilimumab Combo Bests Sunitinib in Advanced RCC
A phase III study by Dr. Robert Motzer and colleagues in NEJM found significantly higher OS and ORRs with the immunotherapy combination. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology News Renal Cell Carcinoma Source Type: news

Belly Fat Lowers Kidney Cancer Survival
The findings suggest kidney cancer develops and progresses differently in men and women, the study authors said. (Source: WebMD Health)
Source: WebMD Health - April 9, 2018 Category: Consumer Health News Source Type: news

Belly Fat Tied to Lower Kidney Cancer Survival Odds in Women
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 9, 2018 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Oncology, Nutrition, News, Source Type: news

Belly Fat Tied to Lower Kidney Cancer Survival Odds in Women
MONDAY, April 9, 2018 -- Belly fat reduces a woman's chances for surviving kidney cancer, but not a man's, a new study suggests. The study included 77 women and 145 men with kidney cancer. Half of the women with high amounts of belly fat died... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 9, 2018 Category: General Medicine Source Type: news

Payments to doctors linked to prescription practices for two cancer types
(UNC Lineberger Comprehensive Cancer Center) Compared to physicians who didn't receive any payments, those who received general payments for meals and lodging from a drug manufacturer had higher odds of prescribing that company's particular drug for metastatic renal cell carcinoma and for chronic myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2018 Category: Cancer & Oncology Source Type: news

New Y-trap Technology Shows Promise as Cancer Immunotherapy
A new technology has shown promise in treating several types of tumors in mice that do not respond to cancer immunotherapy medications called checkpoint inhibitors.04/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 6, 2018 Category: Urology & Nephrology Source Type: news

First-Line Avelumab/Axitinib Encouraging in Advanced RCC
First-line combination therapy with the PD-L1 inhibitor avelumab and the VEGFR TKI axitinib yielded antitumor activity in previously untreated RCC. (Source: CancerNetwork)
Source: CancerNetwork - April 5, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Combinations: The Future of Renal Cell Carcinoma Treatment?
Renal cell carcinoma (RCC) is the most common form of kidney cancer, with an estimated 65,340 patients expected to be diagnosed in 2018 in the United States alone. Nearly a third of those patients will be diagnosed with the advanced or metastatic disease.04/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 5, 2018 Category: Urology & Nephrology Source Type: news

Nivolumab, ipilimumab combination improves advanced renal cell carcinoma survival
Nivolumab plus ipilimumab improved OS and objective response rates compared with sunitinib among patients with intermediate- and poor-risk advanced renal-cell carcinoma, according to findings published in The New England Journal of Medicine.04/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 4, 2018 Category: Urology & Nephrology Source Type: news

TIVO-1 Crossover: Tivozanib Active for Advanced RCC
Compared with sorafenib, tivozanib significantly improved PFS and OS, and yielded significantly higher ORRs, a crossover analysis of TIVO-1 found. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Renal Cell Carcinoma Source Type: news

For women with kidney cancer, belly fat matters
(Washington University School of Medicine) Belly fat affects the odds of women surviving kidney cancer but not men, according to a new study by researchers at Washington University School of Medicine in St. Louis. The findings suggest that kidney cancer may develop and progress differently in women than men. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 3, 2018 Category: International Medicine & Public Health Source Type: news

New Standard of Care in Advanced Renal Cell Carcinoma? New Standard of Care in Advanced Renal Cell Carcinoma?
Combination immunotherapy significantly improved overall survival as compared to standard care with sunitinib as first-line therapy in patients with intermediate- and poor-risk disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 29, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Treatment Options Expanding in Renal Carcinoma
First- and second-line treatment of clear cell RCC has changed dramatically, Dr. Eric Jonasch said during the NCCN Annual Conference in Orlando. (Source: CancerNetwork)
Source: CancerNetwork - March 26, 2018 Category: Cancer & Oncology Authors: Roxanne Nelson Tags: Conferences/NCCN News Renal Cell Carcinoma Source Type: news

EU committee backs dosing changes for Bristol-Myers Squibb ’ s immunotherapy
A committee for the European Union’s pharmaceutical regulatory agency backed changes to the dosing schedule for Bristol-Myers Squibb‘s (NYSE:BMY) Opdivo cancer drug, the company touted today. The Committee for Medicinal Products for Human Use recommended that the European Commission approve a dosing schedule of 480-mg infused over 60 minutes every four weeks as an option for patients with advanced melanoma and previously-treated renal cell carcinoma. The committee also backed a shorter dosing option of 240-mg infused over 30 minutes every two weeks for Opdivo’s six approved monotherapy indications in...
Source: Mass Device - March 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Oncology Pharmaceuticals Regulatory/Compliance Wall Street Beat Bristol-Myers Squibb Co. Source Type: news

Longtime Houston businessman, health care leader dies
A prominent Houston businessman who helped establish Baylor College of Medicine, the Harris County Hospital District and the city's public transportation system has died. Daniel C. Arnold died March 19, according to multiple reports. He had just turned 88 years old. The Houston Chronicle reports that he died from kidney cancer and was surrounded by family at his Houston home.  The native Houstonian was a graduate of the Kinkaid School and attended classes at Rice University and Princeton University… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 21, 2018 Category: American Health Authors: Jen Para Source Type: news

Longtime Houston businessman, health care leader dies
A prominent Houston businessman who helped establish Baylor College of Medicine, the Harris County Hospital District and the city's public transportation system has died. Daniel C. Arnold died March 19, according to multiple reports. He had just turned 88 years old. The Houston Chronicle reports that he died from kidney cancer and was surrounded by family at his Houston home.  The native Houstonian was a graduate of the Kinkaid School and attended classes at Rice University and Princeton University… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 21, 2018 Category: Biotechnology Authors: Jen Para Source Type: news

UPDATE: Boston Scientific lays out $406m for NxThera which plans spin-out of cancer treatment tech
Updated to include commentary from NxThera prez & CEO Bob Paulson. Boston Scientific (NYSE:BSX) said today that it laid out a $406 million deal for NxThera and its Rezūm benign prostatic hyperplasia device, which uses steam to ablate excess prostate tissue. The deal calls for $306 million in up-front cash from Marlborough, Mass.-based Boston Scientific, with another $100 million in potential milestones over the next four years. Boston, which in December 2015 led a $40 million funding round for NxThera, said the existing investment means it will have to put $240 million down and another $8...
Source: Mass Device - March 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat Boston Scientific NxThera Inc. Source Type: news

Certain Patient Subgroups May Benefit from Partial vs Radical Nephrectomy
In this large Chinese study, in certain subgroups cancer-specific survival outcomes were better with partial rather than radical nephrectomy. (Source: CancerNetwork)
Source: CancerNetwork - March 7, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Certain RCC Subgroups May Benefit From Partial vs Radical Nephrectomy
In a large Chinese study, in certain RCC subgroups cancer-specific survival outcomes were better with partial rather than radical nephrectomy. (Source: CancerNetwork)
Source: CancerNetwork - March 7, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Antibiotics Could Reduce Diarrhea, Improve Outcomes in Metastatic RCC
Patients who received Bacteroides-targeting antibiotics had a median PFS of 18 months compared with 8 months in patients with no antibiotic use. (Source: CancerNetwork)
Source: CancerNetwork - March 2, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Infection News Renal Cell Carcinoma Source Type: news

45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
A 45-year-old female presents with gross hematuria 5 days after a laparoscopic partial nephrectomy for renal cell cancer. What is your diagnosis? (Source: CancerNetwork)
Source: CancerNetwork - March 1, 2018 Category: Cancer & Oncology Authors: Brian Morse, MD Tags: Image IQ Source Type: news

Kidney cancer warning - why you should never ignore a pain in your side
CANCER symptoms usually include an unexplained change in the body ’s normal processes. But, having a pain in your side that doesn’t go away could be a sign of kidney cancer, and you should see a doctor. (Source: Daily Express - Health)
Source: Daily Express - Health - February 23, 2018 Category: Consumer Health News Source Type: news

EU Says Yes to Mylotarg for AML, No to Adjuvant Sunitinib EU Says Yes to Mylotarg for AML, No to Adjuvant Sunitinib
Gemtuzumab ozogamicin (Mylotarg) has been recommended for approval in Europe for use in acute myeloid leukemia, but adjuvant sunitinib after kidney cancer surgery was turned down.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Kidney cancer symptoms: A pain in your side could be a sign of deadly disease
CANCER symptoms usually include an unexplained change in the body ’s normal processes. But, having a pain in your side that doesn’t go away could be a sign of kidney cancer, and you should see a GP. (Source: Daily Express - Health)
Source: Daily Express - Health - February 23, 2018 Category: Consumer Health News Source Type: news

When you have kidney cancer...
There's one important thing to remember, when you've been diagnosed with kidney cancer. What is it?02/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 21, 2018 Category: Urology & Nephrology Source Type: news

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1) improve survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To identify genomic alterations in ccRCC that correlate with response to anti–PD-1 monotherapy, we performed whole-exome sequencing of metastatic ccRCC from 35 patients. We found that clinical benefit was associated with loss-of-function mutations in the PBRM1 gene (P = 0.012), which encodes a subunit of the PBAF switch-sucrose nonfermentable (SWI/SNF) chromatin remodeling complex. We confirmed this finding in an independent validation cohort of 63 c...
Source: ScienceNOW - February 15, 2018 Category: Science Authors: Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bosse, D., Wankowicz, S. M., Cullen, D., Horak, C., Wind-Rotolo, M., Tracy, A., Giannakis, M., Hodi, F. S., Drake, C. G., Ball, M. W., Allaf, M. E., Snyder, A., Hellmann, Tags: Medicine, Diseases reports Source Type: news

' Unprecedented' 73% Response Rate With Combo in Untreated RCC'Unprecedented' 73% Response Rate With Combo in Untreated RCC
The combination of an immunotherapy and a VEGF inhibitor for the initial treatment of advanced renal cell carcinoma yielded groundbreaking results. And it is not intolerably toxic.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Kidney cancer symptoms – why you should never ignore loss of appetite
CANCER symptoms are different for each type of the disease. But, you should ignore loss of appetite, as it could be a sign of kidney cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - February 14, 2018 Category: Consumer Health News Source Type: news

New immunotherapy combination tolerable, effective in patients with advanced kidney cancer
(Georgetown University Medical Center) Combining an anti-angiogenesis agent, which blocks blood vessel formation, with an immunotherapy agent, was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 10, 2018 Category: Cancer & Oncology Source Type: news

Roche notches fresh win amid crowd of immunotherapy cocktails
ZURICH (Reuters) - Roche's Tecentriq mixed with an older drug cut the risk of death in kidney cancer, marking another win for the Swiss drugmaker's immuno-oncology (I/O) cocktail as it battles better-established medicines made by its rivals. (Source: Reuters: Health)
Source: Reuters: Health - February 6, 2018 Category: Consumer Health News Tags: healthNews Source Type: news